Introduction: Surgical resection is a standard treatment for thymic malignancies. However, prognostic significance of nodal metastases and lymph node dissection remains unclear. The aim of this study is to determine prognostic significance of nodal metastases and the role of lymph node dissection (LND) in thymic malignancies.
Introduction
Macroscopic and microscopic complete resection is the most important goal of surgical treatment in thymic malignancy. Radical thymectomy of thymic tumor and surrounding thymic tissue is the best way to achieve complete resection. It has been established as the standard treatment for thymic malignancy. However, whether additional lymph node dissection (LND) is necessary during thymectomy remains controversial because actual incidence of lymph node metastasis has not been well known and the therapeutic role of LND in thymic malignancies has not been established. 1 Considering that LND is an important surgical procedure for staging and treatment in patients with many other solid malignancies, the need to establish the role of LND in thymic malignancies has been increasing. In 2013, the International Thymic Malignancy Interest Group (ITMIG) and the International Association for Study of Lung Cancer (IASLC) proposed a new lymph node map and separate N stage in the eighth edition of TNM stage classification system for thymic malignancies. 2, 3 Systematic lymph node sampling in thymoma and LND in thymic carcinoma were suggested by ITMIG. However, evidence supporting routine LND during thymectomy is insufficient.
To address the issue of LND in thymic malignancy, in this collaborative effort, authors of this study collected data on patients who underwent surgical resection for primary thymic malignancies. The objective of the present study was to verify prognostic implications of lymph node metastases and the role of LND in thymic malignancies by retrospectively reviewing a multicenter database in a large-scale investigation.
Material and Methods

Study Design and Patients
We compiled a database of 1597 patients with primary thymic epithelial tumor who were treated between 2000 and 2013 from four institutions. All institutions were tertiary referral hospitals with specialized thoracic surgical centers. All patients had pathologically proven thymic malignancies, including thymoma and thymic carcinoma. Thymic neuroendocrine carcinomas were grouped into thymic carcinomas. Patients with macroscopic incomplete resection (R2) were excluded. Of patients included, 1315 (82.3%) had thymomas and 282 (17.7%) had thymic carcinomas (Fig. 1) . Histologic subtypes based on the Muller-Hermelink classification before 2001 were converted to the corresponding WHO histologic classification of tumors of the thymus. We adopted the ITMIG/IASLC lymph node map and the eighth edition of IASLC/ITMIG TNM stage classification system for thymic malignancies. 2, 3 To identify the effect of LND on short-term and long-term outcomes, we compared patients according to the commitment of LND: patients who received intentional LND (LNDþ group) and those who did not receive intentional LND (LNDgroup).
LND
The standard procedure in the database was total thymectomy through median sternotomy or minimally invasive surgery (MIS) such as thoracoscopic or robotic surgery. An en bloc resection of the adjacent structure(s) was performed in all cases with signs of invasion. Perithymic lymph nodes were dissected en bloc with the tumor and the thymus. Other distant lymph nodes were dissected separately. The extent of LND was decided based on tumor extent and surgeons' preference. During the study period, each lymph node was classified according to the nomenclature of the lung cancer lymph node map. Lymph node stations were reclassified according to the new ITMIG/IASLC lymph node map. 3 Anterior regional stations (N1) included the lower anterior cervical, perithymic, prevascular, para-aortic, superior phrenic, supradiaphragmatic, inferior phrenic, and pericardial node groups. Deep regional stations (N2) included the deep cervical, supraclavicular, upper and lower paratracheal, subaortic, subcarinal, hilar, and internal mammary node groups. All lymph nodes outside anterior or deep regions were regarded as M components. Elective node dissection was defined as the intentional operative procedure when the lymph nodes were dissected separately from thymus. We reviewed all operative reports and pathologic reports and selected the patients who met the above-mentioned criteria. We did not classify the cases which had incidentally detected lymph nodes in resected thymic tissue as elective nodal dissection.
Follow-up
All patients who underwent surgical resection were followed-up from the day of surgery. Postoperative follow-up procedures, including physical examination and chest radiograph every 3 months and a chest computed tomography (CT) scan examination every 6 months, were performed for the first 2 years after operation. Subsequently, physical examination and chest radiography were performed every 6 months, and a chest CT examination was performed every year. Whenever recurrence was suspected, we attempted to obtain histologic or unequivocal radiologic proof. Recurrence was classified in to locoregional recurrence and distal metastasis. In lost cases, a request on the Korean national health data base was conducted to determine outcomes. Operative mortality was defined as 30-day mortality or in-hospital mortality. Freedom from recurrence (FFR) was defined as the time from the date of operation to recurrence.
Statistical Analysis
Propensity scores were calculated from logistic regression models, including the following variables: sex, age, comorbidity, Eastern Cooperative Oncology group performance status, history of myasthenia gravis, tumor size, clinical stage according to TNM stage classification system for thymic malignancies, lymph node enlargement in chest CT and R status. They were used to represent the probability of being assigned to either LNDþ group or LND-group. We matched propensity scores one by one using nearest neighbor methods, no replacement, and a 0.1-caliper width, leading to 297 patients from the LNDþ group matching with 297 patients from the LND-group for thymomas, and 91 patients from the LNDþ group and 91 patients from the LND-group for thymic carcinomas. For comparison between matched groups, Student's t test or Wilcoxon rank sum test was used to compare continuous variables depending on the normality of distribution. The chi square test or Fisher's exact test was used to compare categorical variables. Overall survival rate and FFR rate were estimated using the Kaplan-Meier method. Significance of difference was examined using the log rank test. A multivariate analysis with the Cox proportional hazards model was performed to determine which factors were significantly associated with survival. All statistical tests were two-sided, with significance level set at 0.05. All analyses were performed using SPSS software (version 21, IBM, Armonk, New York).
Results
Patients' Characteristics
From January 2000 to December 2013, a total of 1597 patients were enrolled for the analysis, including 1315 (82.3%) patients with thymoma and 282 (17.2%) patients with thymic carcinoma. LND was performed in 446 (27.9%) patients. It was performed more frequently in patients with thymic carcinoma (n ¼ 148, 52.5%) than thymoma. (n ¼ 298, 22.7%, p < .001) Demographic characteristics of patients who underwent LND are presented in Table 1 . In comparison between patients with and without lymph node metastasis, patients with lymph node metastasis had larger tumor size (p ¼.02) and higher grade in histology subtype (such as B2, B3 thymoma, and thymic carcinoma) (p <.001) than those without lymph node metastasis.
Propensity scores were obtained by previously described statistical methods and propensity score matching was performed according to the model. Demographic and clinical parameters were compared for thymoma and thymic carcinoma. (Table 2 ) The distribution of baseline patient characteristics was well balanced between LNDþ groups and LND-groups for both thymoma and thymic carcinoma after propensity score matching.
Lymph Node Metastasis
A total of 3987 lymph nodes were removed by LND. The mean number of dissected lymph nodes per patient was 8.9 ± 7.8 (range, 1 to 50). Anterior region lymph nodes (N1) were dissected in all patients whereas deep region lymph nodes (N2) were dissected in 224 (50.2%) patients. Patients undergoing open surgery actually had a greater number of lymph nodes (9.6 ± 8.8 versus 7.0 ± 5.4, p ¼ .01) and more N2 dissections (4.6 ± 7.0 versus 2.0 ± 3.7, p < .01) compared to patients undergoing MIS. However, the number of dissected N1 nodes was not different by surgical approach (5.0 ± 4.3 versus 5.0 ± 4.3, p ¼.93).
Lymph node metastasis was identified in 67 (15.0%) patients. Locations of metastasis were N1 stations in 43 (9.6%) patients and N2 stations in 24 (5.4%) patients. All patients underwent preoperative workup with CT chest scanning. The positron-emission tomography-CT scan was performed in 478 patients (29.9%) and magnetic resonance imaging was performed in 114 patients (7.1%). Forty-nine (11.0%) patients had lymph node enlargement in preoperative chest CT. Among those who exhibited lymph node enlargement preoperatively, lymph node metastasis was confirmed in 19 (4.2%) patients ( Table 1) .
The rate of lymph node metastasis of thymic carcinoma was significantly higher than that of thymoma (31.8% versus 6.7%, p < 0.001). Lymph node metastasis rates according to WHO histologic type were 5% for type A, 1.6% for type AB, 4.8% for type B1, 9.5% for type B2, 10.7% for type B3, and 31.8% for thymic carcinoma. In univariable analysis ( The presence of lymph nodal metastases led to upstaging of thymic malignancies in a significant number of patients. LND resulted in upstaging of 13 (4.5%) patients with thymoma and 32 (23.0%) patients with thymic carcinoma who had no evidence of lymph node metastasis in preoperative workup. The clinical stages of the upstaged patients were cT1aN0M0 in 24, cT1bN0M0 in 8, cT2N0M0 in 1, cT3N0M0 in 9 and cT4N0M0 in 3 patients. They would not have been classified as stage IV thymic malignancies if LND had not been performed in those patients.
Prognosis and Role of LND
The median follow-up duration was 171 months. The 5-year/10-year overall survival rate and FFRs were 84.5%/68.7% and 83.5%/70.1%, respectively. Isolated lymph node recurrence was detected in 11 patients with thymic carcinoma and three patients with thymoma in long-term follow-up. Ten patients had lymph node metastasis at the time of operation and four other patients did not. Isolated lymph node recurrence was identified in 16 lymph node stations in 14 patients. Lymph node stations of recurrence included supraclavicular lymph nodes (n ¼ 6), deep cervical lymph nodes (n ¼ 3), paratracheal lymph node (n ¼ 2), supradiaphragmatic lymph node (n ¼ 2), subcarinal lymph node (n ¼ 1), hilar lymph node (n ¼ 1), and subaortic lymph node (n ¼ 1). Figure 2A shows the FFR curves according to N stages of thymic malignancies in patients who underwent LND. The 10-year FFR rate was 78.5% in the N0 group, 31.5% in the N1 group, and 12.3% in the N2 group (p < 0.001). Significant difference in FFR rate was observed between each N stage. Lymph node metastasis was a significant, independent, and adverse factor for FFR in patients with thymoma and thymic carcinoma. Survival benefit of LND was evaluated by comparing the 10-year FFR rate in thymoma and thymic carcinoma after propensity score matching. For thymoma, the 10-year FFR rate was 82.4% in the LNDþ group and 80.9% in the LND-group (p ¼ 0.46) (Fig. 2B) . For thymic carcinoma, the 10-year FFR rate was 45.7% in the LNDþ group and 44.0% in the LNDgroup (p ¼ 0.42) (Fig. 2C ). There was no significant difference in the FFR rate between LNDþ and LNDgroups. Survival benefit of LND could not be identified in thymic malignancies.
Discussion
In the present study, we sought to identify risk factors of lymph node metastasis and the role of LND using a multicenter database. A significant number of patients (27.9%) underwent intentional LND and lymph node metastasis was identified in 6.7% and 31.8% of patients with thymoma and thymic carcinoma, respectively. LND upstaged thymic malignancies in 4.1% and 24.8% of patients with thymoma and thymic carcinoma, respectively (Table 4 ). The prognostic role of LND was evaluated by comparing 10-year FFR rates between LNDþ and LND-groups after propensity score matching. However, we could not find significant difference in long-term recurrence rate between LNDþ and LNDgroups.
The first proposal of lymph node staging for thymic malignancies was suggested by Yamakawa et al. 4 in 1991. They suggested three lymph node groups: perithymic as N1, intrathoracic as N2, and extrathoracic as N3 lymph nodes. Although they did not provide detailed definition for each lymph node station, it became the basis of lymph node staging in later studies. Recently, ITMIG and IASLC have proposed a lymph node map for thymic malignancies that supports a new TNM classification for thymic tumors and re-emphasizes lymph node metastasis in thymic malignancy. 2, 5 Historically, incidence of lymph node metastasis in thymic malignancies has been underestimated. This has received little attention until recently. Actual incidence of lymph node metastasis in thymic malignancy has not been well documented. Because LND is performed sporadically depending on surgeons' policy, systematic LND has only been applied in a small number of patients. Kondo and Monden 6 have compiled a Japanese multicenter database of 1320 patients with thymic malignancies. The overall incidence of lymph node metastasis was 5.9% (1.8% and 27% in patients with thymoma and thymic carcinoma, respectively). Gu et al. 7 have reported an overall incidence of 2.2% in 1617 patients using a Chinese multicenter database. Those two studies from Eastern countries reported low incidence of lymph node metastasis. However, studies from the United States have reported high lymphatic spread rate: 13.3% of 440 thymomas from the Surveillance, Epidemiology, and End Results program database. 8 The difference in metastatic rate might be due to differences in inclusion criteria. The study using the Surveillance, Epidemiology, and End Results database included only patients who had at least one lymph node analyzed pathologically. 8 This might have included patients who underwent LND. Our data also clearly showed that LND increased the lymph node metastasis rate. The overall rate of lymph node metastasis in all patients was 4.2%. It was increased up to 15.0% in patients who underwent LND. The actual lymph node metastasis rate would be higher than previous reports. However, currently, we do not have exact data on lymph node metastasis rate in thymic malignancy. A prospective study for systematic LND in thymic malignancy is necessary.
Several risk factors for lymph node metastasis were identified in this study. The first was the WHO subtype. The rate of lymph node metastasis of thymic carcinoma was significantly higher than that of thymoma. Type B2 and B3 thymomas showed significantly higher rate of lymph node metastasis than type A, AB, and B1 thymomas in this study. The WHO subtype had been suggested as a significant risk factor for lymph node metastasis in previous studies. In a previous single-center study, higher lymph node metastasis rate was reported in type B2 and B3 thymomas and thymic carcinoma. However, no lymph node metastasis was identified in type A, AB, or B1 thymomas. 9 Likewise, the WHO subtype was one of the independent factors for lymph node metastasis in thymic malignancies according to a Chinese multicenter database study. 7 Lymph node metastases were of B-type, consistent with the more aggressive behavior of B-type thymoma and morphological hallmarks of B-type thymoma (i.e., perivascular spaces and perivascular palisades of epithelial cells were retained in lymph node metastases). [10] [11] [12] Apart from WHO subtypes, tumor size was a risk factor of lymph node metastasis in this study. Lymph node metastasis rate in tumors larger than 6 cm was significantly higher than that in tumors 6 cm or smaller. Tumor size and stage are closely related to each another. 13 Both of them represent biologic aggressiveness or tumor burden. In previous studies, it was difficult to determine more significant predictor of lymph node metastasis between the extension of tumor invasion and tumor size. [6] [7] [8] [9] Higher lymph node metastasis rates in larger tumors irrespective of stages suggest that gross tumor burden can independently affect lymph node metastasis without overt invasiveness of tumors.
Because of the behavior of thymic malignancies, recurrence is a better measure of oncologic outcomes than overall survival. 14 We used FFR as a primary prognostic outcome in this study and compared FFR according to N stages. Similar to many other studies, our study showed that lymph node metastasis was a significant adverse prognostic factor in thymic malignancies.
6,15-20 Weksler et al. 8 have shown that the presence of nodal metastases increases the risk of death by approximately three-fold. In our study, the presence of lymph node metastasis was accompanied by a significantly worse FFR. The difference of FFR in each N stage was well discriminated by the progression of N stages. A significant number of patients could be upstaged to stage IV after LN dissection. More accurate prediction of prognosis was possible in patients who underwent LND. At least we can say that one important role of LND is that it can provide better prediction of prognosis in patients with thymic malignancy. One important role of lymph node dissection is that it can guide adjuvant treatment, thus increasing disease control rate. Nevertheless, no guidelines are available on adjuvant treatment of a patient found to have nodal metastasis after surgical resection in thymic malignancies. No studies have specifically addressed postoperative adjuvant therapy in patients with stage IVB thymic malignancies with node metastases. In our data, the rate of adjuvant treatment was 83.6% in 67 patients with lymph node metastasis. A majority (67.2%) of patients had received radiation therapy. However, only 43.3% had received chemotherapy. In lymph node metastasis patients, the 5-year FFR rate was 23.5% in the adjuvant treatment group and 32.8% in the non-adjuvant treatment group. There was no significant (p ¼ 0.64) difference in adjuvant therapy rate according to lymph node dissection. Because the protocol of adjuvant therapy on nodal-positive patients had not been standardized between institutes, we could not verify the impact of adjuvant treatment on thymic malignancies. LND is an important procedure for staging, planning treatment, and evaluating treatment efficacy in patients with other solid malignancies. Routine LND is generally recommended. 1, 21 However, due to insufficient evidence on the role of LND, whether routine LND is necessary in thymic malignancy remains unclear. ITMIG has proposed that anterior mediastinal nodes should be routinely removed along with the thymus. It encourages systematic sampling of deep nodes when resecting thymic malignancies for accurate lymph node staging. 5 However, oncologic benefit of LND in survival or recurrence has not been documented yet. In this study, we tried to evaluate the effect of LND on FFR with long-term followup. To minimize selection bias of LND, we selected wellmatched groups using propensity score matching for thymoma and thymic carcinoma, respectively. Consequently, we found no differences in FFR rate between LNDþ and LND-groups. Benefits of LND on recurrence of thymoma or thymic carcinoma were not identified in our study either. Park et al. 21 have reported that anterior and paratracheal nodes should be routinely dissected in thymic carcinoma, especially when adjacent organs are invaded. A minimum number of 10 dissected lymph nodes were suggested in their study as this appeared to correlate with better survival. However, we could not verify such effect in this study. Such difference in outcome might be related to difference in study design. Many thoracic surgeons in multi-institutions have different standards for LND based on surgical approach as well as pre-and intraoperative findings. Recently, use of MIS approaches such as video-assisted thoracoscopic surgery and robot assisted thoracic surgery on thymic malignancies has been gradually increasing. Our data has shown that LND was performed more frequently in preoperative mediastinal lymph node enlargement on CT or in cases where the open surgical approach was used such as median sternotomy (Table 4) . Patients undergoing open surgery actually had a greater number of lymph nodes and more N2 dissections compared to patients undergoing MIS. However, the number of dissected N1 nodes was not different by surgical approach. It was different because N1 lymph node dissection was relatively easier than N2 lymph node dissection in MIS, which could be performed with thymectomy concomitantly in most cases. However, N2 lymph node dissection required a wider surgical view, which was not always possible in MIS. Furthermore, the extent of LND had not been standardized between institutes. Consequently, extents and numbers of LNDs were heterogeneous. We included more patients from the multicenter trial, analyzed thymoma and thymic carcinoma separately, and used propensity score matching to reduce potential bias. According to the results of our study, improvement of oncologic outcome by LND was not identified.
This study had several limitations. First, there was no consistent LND protocol at the time of the study between institutes. On the basis of reviewing pathologic and operating reports, we defined intentional LND as the procedure that was routinely performed by resection of perithymic lymph nodes and/or intrathoracic lymph nodes. Many thoracic surgeons in multi-institutions had different standards for LND based on pre-and intraoperative findings. Therefore, extents and numbers of LNDs were heterogeneous. Adoption of ITMIG proposals and recommendation might allow more uniform data collection and facilitate research on LND in thymic malignancy in the near future. Second, only a limited number of patients had sufficient detailed data to allow evaluation of outcomes for adjuvant treatment. Whether lymph node metastasis affected the decision of adjuvant treatment and selection of type of adjuvant treatment was not well documented in the database. Therefore, the role of adjuvant treatment in lymph node metastasis could not be evaluated in this study.
In conclusion, lymph node metastasis was a significant risk factor for long-term recurrence in thymic malignancy. Thymic carcinoma and tumor size were independent risk factors for lymph node metastasis in this study. Although LND increased the detection of occult lymph node metastasis and enabled better prediction of prognosis, long-term oncological outcome on recurrence was not improved by LND. Prospective multicenter studies on LND using standardized LND protocol are necessary in the future.
